These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26653838)

  • 1. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems.
    Rodríguez-Nogales C; Garbayo E; Carmona-Abellán MM; Luquin MR; Blanco-Prieto MJ
    Maturitas; 2016 Feb; 84():25-31. PubMed ID: 26653838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
    Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
    J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
    Sass MB; Lorenz AN; Green RL; Coleman RA
    J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanodelivery of therapeutic agents in Parkinson's disease.
    Lafuente JV; Requejo C; Ugedo L
    Prog Brain Res; 2019; 245():263-279. PubMed ID: 30961870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.
    Hashimoto M; Kawahara K; Bar-On P; Rockenstein E; Crews L; Masliah E
    J Mol Neurosci; 2004; 24(3):343-52. PubMed ID: 15655259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha-synuclein in Parkinson's disease].
    Oczkowska A; Kozubski W; Dorszewska J
    Przegl Lek; 2014; 71(1):26-32. PubMed ID: 24712265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids.
    Kubo SI
    Expert Opin Ther Targets; 2016 Nov; 20(11):1301-1310. PubMed ID: 26610255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease: a short story of 200 years.
    Cuenca L; Gil-Martinez AL; Cano-Fernandez L; Sanchez-Rodrigo C; Estrada C; Fernandez-Villalba E; Herrero MT
    Histol Histopathol; 2019 Jun; 34(6):573-591. PubMed ID: 30540129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathological mechanisms of Parkinson's disease].
    Matsui H; Takahashi R
    Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of Parkinson's disease.
    Gandhi S; Wood NW
    Hum Mol Genet; 2005 Sep; 14(18):2749-55. PubMed ID: 16126732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management.
    Sola P; Krishnamurthy P; Chintamaneni PK; Pindiprolu SKSS; Kumari M
    Expert Opin Drug Deliv; 2020 Aug; 17(8):1119-1132. PubMed ID: 32497457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
    Lo Bianco C; Déglon N; Pralong W; Aebischer P
    Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis of cell death in Parkinson's disease--2007.
    Olanow CW
    Mov Disord; 2007 Sep; 22 Suppl 17():S335-42. PubMed ID: 18175394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
    Ko WKD; Bezard E
    Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.